.jpg)
In our recent webinar, From Scientific Noise to Strategic Insight: Building a Modern Competitive & Market Intelligence Function in Life Sciences, Northern Light's Chief Product Officer, Sheri Larsen, and VP of Marketing, Sarah Hughes, explored a pressing question for life sciences organizations:
How do you build a competitive and market intelligence (CI) function that keeps up with today’s speed, complexity, and regulatory pressure?
For CI leaders supporting R&D, medical affairs, and commercial strategy, the stakes are clear. The volume of scientific, clinical, and competitive data has exploded, but the ability to turn that data into decision-ready insight has not kept pace.
This session unpacked what’s broken, and what a modern, scalable CI function actually looks like in practice.
Key Takeaway #1: Fragmentation is the Real Problem
Life sciences organizations aren’t lacking information. They’re overwhelmed by it.
From clinical trials and regulatory updates to conference abstracts and scientific literature, the volume of signals has grown beyond what traditional workflows can handle. The issue isn’t access—it’s disconnection.
As highlighted in the session, analysts now spend 60–70% of their time gathering information instead of analyzing it.
That imbalance creates real risk:
- Critical competitive signals are missed
- Insights arrive too late to influence decisions
- Teams operate on incomplete or outdated intelligence
In a molecule-to-market environment where timing is everything, fragmentation isn’t just inefficient, it’s a strategic liability.
Key Takeaway #2: Manual CI Models Can’t Keep Up with Market Speed
Five years ago, CI teams had months to respond to competitive developments.
Today, that window has collapsed to weeks or even hours.
Yet many life sciences organizations still rely on manual workflows:
- Building pipeline maps and competitor landscapes
- Monitoring conferences in real time
- Assembling fact packs and executive briefings
These outputs are valuable—but the process behind them is no longer sustainable at scale.
The result is “insight lag”: by the time intelligence reaches stakeholders, the opportunity to act has already passed.
Key Takeaway #3: Modern CI Requires a Connected Intelligence Environment
To operate at today’s speed, CI must evolve from a collection of workflows into a connected, enterprise intelligence capability.
That shift starts with unification.
A modern CI environment brings together:
- Internal research and institutional knowledge
- Licensed external content and analyst reports
- Open-source intelligence (clinical, regulatory, scientific)
But the real transformation isn’t just aggregation—it’s activation.
Leading organizations are shifting from:
- Research → Decision enablement
- Static reports → Continuous insight delivery
- Siloed teams → Cross-functional intelligence sharing
This matters in life sciences, where R&D, regulatory, and commercial teams must align around the same signals. When everyone operates from a shared intelligence foundation, decisions become faster, more consistent, and more defensible.
Key Takeaway #4: AI Only Delivers Value If It’s Trusted, Governed, and Embedded
AI adoption is accelerating across life sciences—but trust remains the barrier.
Generic AI tools introduce real risks:
- Hallucinated or unverifiable insights
- Lack of transparency into sources
- Use of unlicensed or non-compliant content
In a regulated industry, that’s unacceptable.
The webinar emphasized that enterprise AI must be built differently. Specifically, it must include:
- Source traceability: Every output tied to verifiable, citable sources
- Licensed, governed content: Ensuring compliance with copyright and regulatory standards
- Governance support: Aligning with internal approval processes
- Workflow integration: Delivering insights where teams already work
This aligns with a broader industry shift: AI is only as valuable as the data foundation behind it. Without trusted, governed intelligence, AI accelerates noise—not insight.
Real-World Impact: How a Top Pharma Company Transformed CI
One example from the session illustrates what this transformation looks like at scale.
A top five global pharmaceutical company faced a familiar challenge: intelligence existed everywhere but was difficult to find, share, and act on.
After implementing a unified intelligence platform:
- 15,000 users across R&D, medical, and commercial teams accessed the same environment
- Disconnected tools and repositories were consolidated into a single system
- CI teams began delivering daily executive briefings before 6 a.m. ET
The impact was measurable:
- $5M+ in annual productivity gains
- 3x faster time from signal to decision
- Expanded coverage across therapeutic areas and geographies
- Elimination of conflicting insights across teams
Perhaps most telling: when a daily briefing was delayed by just minutes, executives immediately noticed. CI had moved from a support function to a mission-critical capability.
What This Means for Life Sciences CI Leaders
The webinar closed with four principles that should guide the next phase of CI transformation:
1. Complexity Will Only Increase
Scientific, regulatory, and competitive landscapes are becoming more dynamic—not less. CI functions built for yesterday’s environment will fall behind.
2. Integration Must Come First
Before investing in more data or AI tools, organizations must solve fragmentation. A unified intelligence foundation is the prerequisite for scale.
3. CI Must Drive Decisions—Not Just Deliver Insights
The value of CI isn’t measured by reports produced, but by decisions improved—from pipeline prioritization to market strategy.
4. Platforms + Governed AI Enable Scale
The organizations leading in CI are combining purpose-built platforms with trusted, enterprise-ready AI—allowing them to move faster without sacrificing accuracy or compliance.
Watch the Full Webinar
Want to see how leading life sciences organizations are operationalizing these principles?
Watch the full session on demand.
.jpg)
